BioStock Studio: Aptahem’s CEO on upcoming milestones
Aptahem has taken several steps forward in 2022. Recently, the biotech company passed a milestone with the start of the clinical phase I study with the sepsis candidate Apta-1. CEO Mikael Lindstam visited BioStock’s studio to present the company and answer questions about the rights issue that is currently underway.
Watch the presentation and interview with Aptahem’s CEO Mikael Lindstam at aptahem.com:
For further information:
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.